Patents by Inventor Sumeet K. Mittal

Sumeet K. Mittal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systems and methods for Barrett's esophagus pathogenesis and esophageal adenocarcinoma progression revealing markers
    Patent number: 11874277
    Abstract: Methods are provided for assessing risk of developing esophageal adenocarcinoma in a subject using one or more of the following marker genes/proteins: ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. Methods are also provided for determining expression of one or more esophageal adenocarcinoma risk factors in a subject. Methods are also provided for treating esophageal adenocarcinoma in a subject, for preventing esophageal adenocarcinoma in a subject, for inhibiting or decreasing proliferation of esophageal adenocarcinoma cells, for inhibiting or decreasing migration of esophageal adenocarcinoma cells, or for increasing susceptibility to cytotoxicity or inducing cell death of esophageal adenocarcinoma cells.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: January 16, 2024
    Assignee: PROPHASE LABS, INC.
    Inventors: Joe Abdo, Sumeet K. Mittal, Devendra K. Agrawal
  • SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERS
    Publication number: 20210364521
    Abstract: Methods are provided for assessing risk of developing esophageal adenocarcinoma in a subject using one or more of the following marker genes/proteins: ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. Methods are also provided for determining expression of one or more esophageal adenocarcinoma risk factors in a subject. Methods are also provided for treating esophageal adenocarcinoma in a subject, for preventing esophageal adenocarcinoma in a subject, for inhibiting or decreasing proliferation of esophageal adenocarcinoma cells, for inhibiting or decreasing migration of esophageal adenocarcinoma cells, or for increasing susceptibility to cytotoxicity or inducing cell death of esophageal adenocarcinoma cells.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 25, 2021
    Inventors: Joe Abdo, Sumeet K. Mittal, Devendra K. Agrawal